Registered title, quoted from ClinicalTrials.gov
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06879470, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Eastern Cooperative Oncology Group(ECOG) score of 0 to 1 at baseline;
Inclusion criterion 7
Albuminous aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN);
Inclusion criterion 9
Albumin transaminase (AST) ≤ 3 times the ULN;
Inclusion criterion 10
Total bilirubin ≤ 1.5 times the ULN;
Inclusion criterion 11
Serum creatinine ≤1.5 times ULN or creatinine clearance ≥30 mL/min;
Inclusion criterion 12
The presence of at least one measurable lesion on imaging of relapsed or refractory B-cell lymphoma, i.e., a lymph node lesion >15 mm in length or an extranodal lesion >10 mm in length based on CT cross-sectional images, along with a positive Fluorodeoxyglucose Computed Tomography(FDG-PET).
Inclusion criterion 5
Primary malignant tumor that has been completely resected and in complete remission for ≥ 5 years.
Exclusion criterion 10
Women who are pregnant or breastfeeding, and female subjects who plan to become pregnant within 2 years of their JY231 injection infusion or male subjects whose partners plan to become pregnant within 2 years of their JY231 injection infusion;
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06879470, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Subjects voluntarily signed an informed consent form and were willing and able to comply with all study requirements;
- Age 18\~75 years old, gender is not limited;
- Malignant tumor cells positive for Cluster of Differentiation 19(CD19);
- Meet the criteria for relapsed or refractory B-cell lymphoma. Relapsed: the subject's tumor reappears after achieving complete remission of the disease; refractory: the subject is ineffective or in only partial remission on standard treatment regimens. Subjects must have relapsed or become refractory after receiving at least two lines of systemic therapy or autologous hematopoietic stem cell transplantation.
- The presence of at least one measurable lesion on imaging of relapsed or refractory B-cell lymphoma, i.e., a lymph node lesion >15 mm in length or an extranodal lesion >10 mm in length based on CT cross-sectional images, along with a positive Fluorodeoxyglucose Computed Tomography(FDG-PET).
- Expected survival ≥12 weeks;
- Eastern Cooperative Oncology Group(ECOG) score of 0 to 1 at baseline;
- Good organ function (the standard can be appropriately relaxed for indicators involving liver and kidney function)
- Albuminous aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN);
- Albumin transaminase (AST) ≤ 3 times the ULN;
- Total bilirubin ≤ 1.5 times the ULN;
- Serum creatinine ≤1.5 times ULN or creatinine clearance ≥30 mL/min;
- Room oxygen saturation ≥92% without oxygen;
- left ventricular ejection fraction (LVEF) ≥50%;
- Men of childbearing potential to ensure effective contraception for sexual partners; women of childbearing potential to use effective contraception and agree to use contraception throughout the study period.
Exclusion Criteria:
- Subjects with active central nervous system (CNS) lymphoma;
- Subjects with a history of active CNS disease such as seizures, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement;
- Subjects who have been treated with another investigational drug within 30 days prior to screening or are still in the washout period;
- Subjects who have had radiation therapy within 2 weeks prior to infusion;
- Subjects with uncontrolled acute life-threatening bacterial, viral, or fungal infections (e.g., positive blood cultures ≤ 72 hours prior to infusion);
- Subjects with unstable angina and/or myocardial infarction within 6 months prior to Screening;
- Subjects with other prior or concurrent malignancies, with the following exceptions:
- Adequately treated basal cell, papillary thyroid, or squamous cell carcinoma (adequate wound healing is required prior to enrollment in the study);
- Carcinoma in situ of the cervix or breast, curatively treated, with no sign of recurrence for at least 3 years prior to study entry;
- Primary malignant tumor that has been completely resected and in complete remission for ≥ 5 years.
- Presence of subjects with arrhythmias not controlled by medical management;
- Subjects with active neurologic autoimmune or inflammatory conditions (e.g. Guillain-Barre syndrome, amyotrophic lateral sclerosis);
- Women who are pregnant or breastfeeding, and female subjects who plan to become pregnant within 2 years of their JY231 injection infusion or male subjects whose partners plan to become pregnant within 2 years of their JY231 injection infusion;
- Subjects who, in the investigator's judgment and/or clinical criteria, have a contraindication to any of the study procedures or have other medical conditions that may place them at unacceptable risk.
- Other conditions that, in the opinion of the investigator, should not be enrolled in this clinical study, such as poor compliance.
Quoted from ClinicalTrials.gov, NCT06879470, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06879470, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.